

## **Bruno Villoutreix**

Bruno Villoutreix is Director of Research at Inserm, currently leads the UMR Inserm U973 Paris Diderot “Therapeutic Molecules in silico” and is co-director of the Graduate School MTCI (Medicine, Toxicology, Chemistry and Imagery). He is a biologist, bioinformatician and chemoinformatician.

After more than 10 years of research in Sweden, Finland and the USA, in both academia and the private sector, he was appointed Director of Research in the INSERM unit Thrombotic risk and mechanisms of hemostasis (Paris Descartes). He focuses on the structure-function analysis of therapeutic targets involved in blood coagulation and in some cancers and on the rational design of drug candidates using in silico approaches. He contributed greatly to the development of a new anti-metastatic compound currently in clinical trials and has been a consultant for many years for a major pharmaceutical company in the USA.

At 51, he has authored or co-authored more than 190 publications, reviews, patents and book chapters.